

ALS Drug Status

Rank	Drug (link)	Phase	Recruiting	EAP	Phase 3 start	Trial results & outlook
1	QRL-201 (https://clinicaltrials.gov/study/NCT05633459)	Phase 1/2	No recruiting	No	~2027	Strong biomarker + STMN2 restoration
2	SPG302 (https://clinicaltrials.gov/study/NCT05882695)	Phase 1/2a	No	Yes	Unknown	Strong early slowing signal
3	AP-101 (https://clinicaltrials.gov/study/NCT05039099)	Phase 2	No	No	~2026-27	Survival + biomarker improvements
4	PrimeC (https://clinicaltrials.gov/study/NCT05357950)	Phase 2b	No	No	Expected	Slower decline signal
5	COYA-302 (https://clinicaltrials.gov/study/NCT07161999)	Phase 2	Yes	No	Unknown	Immune modulation approach
6	Pridopidine (https://clinicaltrials.gov/study/NCT07322003)	Phase 3	Yes	No	Active	Phase 2 mixed results, Phase 3 ongoing

7	PHENOGENE-1A (https://clinicaltrials.gov/study/NCT07142291)	Phase 2	Yes	Prescription drug	Unknown	Repurposed anti-inflammatory
8	CORT113176 (https://clinicaltrials.gov/study/NCT05407324)	Phase 2	Yes	No	Unknown	No results yet
9	Ranolazine (https://clinicaltrials.gov/study/NCT06527222)	Phase 2	Yes	No	Unknown	Likely symptomatic
10	CNM-Au8 (https://clinicaltrials.gov/study/NCT05281484)	Phase 2/3	No	EAP closed	Unknown	Mixed results
11	Darifenacin (https://clinicaltrials.gov/study/NCT06249867)	Phase 2	Yes	Prescription drug – Avail in Iceland	Unknown	No results yet